Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The quick ratio (acid-test) is N/A as of Tuesday, October 6, 2026.
QUICK RATIO (ACID-TEST)
N/A
Veraxa Biotech Holding AG
Market Cap
$149.89M
Quick Ratio (Acid-Test)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$151.58M
Quick Ratio (Acid-Test)
5.55
TTM Avg
4.34
3Y Avg
4.83
5Y Avg
5.44
Market Cap
$147.13M
Quick Ratio (Acid-Test)
7.51
TTM Avg
6.60
3Y Avg
4.97
5Y Avg
4.99
Market Cap
$146.82M
Quick Ratio (Acid-Test)
2.99
TTM Avg
3.92
3Y Avg
3.42
5Y Avg
4.30
Market Cap
$153.09M
Quick Ratio (Acid-Test)
1.69
TTM Avg
1.79
3Y Avg
2.66
5Y Avg
3.67
Market Cap
$146.67M
Quick Ratio (Acid-Test)
9.71
TTM Avg
4.67
3Y Avg
6.04
5Y Avg
19.74
Market Cap
$146.62M
Quick Ratio (Acid-Test)
2.47
TTM Avg
5.26
3Y Avg
13.15
5Y Avg
16.36
Market Cap
$145.68M
Quick Ratio (Acid-Test)
0.82
TTM Avg
5.49
3Y Avg
4.19
5Y Avg
4.19
Market Cap
$145.96M
Quick Ratio (Acid-Test)
15.62
TTM Avg
10.23
3Y Avg
11.93
5Y Avg
11.24
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Veraxa Biotech Holding AG (VRXA) | $149.89M | N/A | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.58M | 5.55 | 4.34 | 4.83 | 5.44 |
| Voyager Therapeutics, Inc. (VYGR)vs › | $147.13M | 7.51 | 6.60 | 4.97 | 4.99 |
| Codexis, Inc. (CDXS)vs › | $146.82M | 2.99 | 3.92 | 3.42 | 4.30 |
| Neuronetics, Inc. (STIM)vs › | $153.09M | 1.69 | 1.79 | 2.66 | 3.67 |
| ALX Oncology Holdings Inc. (ALXO)vs › | $146.67M | 9.71 | 4.67 | 6.04 | 19.74 |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | 2.47 | 5.26 | 13.15 | 16.36 |
| Korsana Biosciences, Inc. (KRSA)vs › | $145.68M | 0.82 | 5.49 | 4.19 | 4.19 |
| Anavex Life Sciences Corp. (AVXL)vs › | $145.96M | 15.62 | 10.23 | 11.93 | 11.24 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $145.89M | 1.23 | 1.14 | 1.35 | 4.96 |
Quick Ratio
N/A
Excludes inventory
Current Ratio
N/A
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
